Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:AUTL NASDAQ:CRGX NASDAQ:DNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.20+6.5%$0.10$0.04▼$0.88$51.95M2.4932.41 million shs162.78 million shsAUTLAutolus Therapeutics$1.67-3.2%$1.62$1.11▼$5.00$443.13M1.842.36 million shs1.91 million shsCRGXCARGO Therapeutics$4.47$4.49$3.00▼$25.45$216.17M0.31.73 million shsN/ADNTHDianthus Therapeutics$36.03-0.5%$30.41$13.36▼$40.16$1.16B1.58426,833 shs310,068 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics+15.06%-12.54%+176.43%-33.42%-79.08%AUTLAutolus Therapeutics+6.17%-2.27%+30.30%-28.93%-59.62%CRGXCARGO Therapeutics0.00%0.00%0.00%-2.61%-79.54%DNTHDianthus Therapeutics+1.86%+4.17%-2.27%+77.89%+31.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.20+6.5%$0.10$0.04▼$0.88$51.95M2.4932.41 million shs162.78 million shsAUTLAutolus Therapeutics$1.67-3.2%$1.62$1.11▼$5.00$443.13M1.842.36 million shs1.91 million shsCRGXCARGO Therapeutics$4.47$4.49$3.00▼$25.45$216.17M0.31.73 million shsN/ADNTHDianthus Therapeutics$36.03-0.5%$30.41$13.36▼$40.16$1.16B1.58426,833 shs310,068 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics+15.06%-12.54%+176.43%-33.42%-79.08%AUTLAutolus Therapeutics+6.17%-2.27%+30.30%-28.93%-59.62%CRGXCARGO Therapeutics0.00%0.00%0.00%-2.61%-79.54%DNTHDianthus Therapeutics+1.86%+4.17%-2.27%+77.89%+31.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 1.88Reduce$1.35589.63% UpsideAUTLAutolus Therapeutics 2.71Moderate Buy$9.12447.75% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.40244.52% UpsideDNTHDianthus Therapeutics 2.82Moderate Buy$60.8868.98% UpsideCurrent Analyst Ratings BreakdownLatest ADAP, DNTH, AUTL, and CRGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025DNTHDianthus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$56.0010/8/2025ADAPAdaptimmune TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DNTHDianthus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ADAPAdaptimmune TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DNTHDianthus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025AUTLAutolus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform9/12/2025DNTHDianthus TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $65.009/12/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $44.009/9/2025DNTHDianthus TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$56.00 ➝ $63.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$65.09M0.80N/AN/A$0.05 per share3.92AUTLAutolus Therapeutics$29.93M14.80N/AN/A$1.61 per share1.03CRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/ADNTHDianthus Therapeutics$4.85M238.89N/AN/A$11.91 per share3.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%11/12/2025 (Estimated)AUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%11/11/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$3.25N/AN/AN/A-2,364.56%-34.72%-32.72%11/6/2025 (Estimated)Latest ADAP, DNTH, AUTL, and CRGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025ADAPAdaptimmune Therapeutics-$0.09N/AN/AN/A$12.31 millionN/A11/11/2025Q3 2025AUTLAutolus Therapeutics-$0.24N/AN/AN/A$21.08 millionN/A11/6/2025Q3 2025DNTHDianthus Therapeutics-$0.88N/AN/AN/A$0.58 millionN/A8/13/2025Q2 2025ADAPAdaptimmune Therapeutics-$0.15-$0.11+$0.04-$0.11$11.04 million$13.68 million8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/7/2025Q2 2025DNTHDianthus Therapeutics-$0.86-$0.88-$0.02-$0.88$0.87 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A1.521.29AUTLAutolus TherapeuticsN/A8.438.07CRGXCARGO TherapeuticsN/A12.3712.37DNTHDianthus TherapeuticsN/A13.1213.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%AUTLAutolus Therapeutics72.83%CRGXCARGO Therapeutics93.16%DNTHDianthus Therapeutics47.53%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%AUTLAutolus Therapeutics25.70%CRGXCARGO Therapeutics2.92%DNTHDianthus Therapeutics8.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million231.28 millionOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/ADNTHDianthus Therapeutics8032.19 million29.57 millionOptionableADAP, DNTH, AUTL, and CRGX HeadlinesRecent News About These CompaniesDianthus Therapeutics Signs License Agreement with Nanjing Leads1 hour ago | msn.comDianthus to license autoimmune disease candidate in a deal worth up $1B1 hour ago | msn.comDianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL ...October 16 at 9:37 AM | finance.yahoo.comDianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Unique Mechanism of ActionOctober 16 at 7:30 AM | quiverquant.comQDianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune DiseasesOctober 16 at 7:00 AM | globenewswire.comTruist Securities Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationOctober 15 at 4:59 AM | msn.comDianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Analysts at Truist FinancialOctober 14 at 9:13 AM | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Dianthus Therapeutics (NASDAQ:DNTH)October 9, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9% - What's Next?October 2, 2025 | marketbeat.comDianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual MeetingOctober 2, 2025 | globenewswire.comClear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price TargetSeptember 30, 2025 | insidermonkey.comClear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price TargetSeptember 30, 2025 | finance.yahoo.comDianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High - Here's WhySeptember 30, 2025 | marketbeat.com11 Best Fast Money Stocks To Buy NowSeptember 29, 2025 | insidermonkey.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 28, 2025 | marketbeat.comGoldman Sachs Group Inc. Has $1.33 Million Stake in Dianthus Therapeutics, Inc. $DNTHSeptember 21, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Here's WhySeptember 18, 2025 | marketbeat.comClear Street Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationSeptember 17, 2025 | msn.comDianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity RaiseSeptember 13, 2025 | finance.yahoo.comDianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 SharesSeptember 12, 2025 | insidertrades.comDianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional ...September 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAP, DNTH, AUTL, and CRGX Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.20 +0.01 (+6.46%) As of 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Autolus Therapeutics NASDAQ:AUTL$1.66 -0.06 (-3.20%) As of 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.CARGO Therapeutics NASDAQ:CRGXCARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Dianthus Therapeutics NASDAQ:DNTH$36.02 -0.18 (-0.48%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
